Literature DB >> 31444144

The Evolution of Fibrosis and Atrophy and Their Relationship with Visual Outcomes in Asian Persons with Neovascular Age-Related Macular Degeneration.

Chui Ming Gemmy Cheung1, Dilraj S Grewal2, Kelvin Yi Chong Teo3, Alfred Gan3, Aditi Mohla3, Usha Chakravarthy4, Tien Yin Wong5, Glenn J Jaffe2.   

Abstract

PURPOSE: To describe the rate of development and progression of fibrosis and macular atrophy (MA) and their relationship with 1-year visual outcomes in Asian participants with neovascular age-related macular degeneration (nAMD).
DESIGN: Review of images collected from a prospectively recruited observational cohort. PARTICIPANTS: Participants with treatment-naïve nAMD.
METHODS: All participants underwent multimodality imaging at baseline and month 12 and were treated according to standard of care. Retinal specialists evaluated color fundus photographs fluorescein and indocyanine green angiography images to determine the subtypes according polypoidal choroidal vasculopathy (PCV) and non-PCV subtypes. An independent reading center graded qualitative and quantitative morphologic features on spectral-domain OCT. Fibrosis and MA were determined based on multimodal imaging. MAIN OUTCOME MEASURES: Incidence of fibrosis and MA and their impact on visual outcome at 1 year.
RESULTS: We included 93 eyes (48.4% PCV). Between baseline and month 12, visual acuity (VA) improved from 0.81±0.56 logarithm of the minimum angle of resolution (logMAR; Snellen equivalent, approximately 20/126) to 0.71±0.61 logMAR (Snellen equivalent, approximately 20/100; P = 0.007), and mean retinal thickness decreased from 471.1 μm to 343.4 μm (P < 0.001). Between baseline and month 12, prevalence of fibrosis and MA increased from 13.0% to 37.8% (P < 0.001) and 9.7% to 17.2% (P = 0.008), respectively. Worse baseline VA and presence of subretinal hyperreflective material (SHRM) at month 12 were associated with worse VA at month 12 after adjusting for multiple factors, whereas PCV subtype was associated with better VA at month 12. At month 12, the predominant composition of SHRM was fibrosis (82.5%).
CONCLUSIONS: We describe significant development of fibrosis and MA in Asian nAMD eyes and show that fibrosis is the most important predictor of outcomes. These results highlight the need for therapy beyond anti-vascular endothelial growth factor inhibition to address fibrosis in Asian nAMD.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31444144     DOI: 10.1016/j.oret.2019.06.002

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  7 in total

1.  7-ketocholesterol induces endothelial-mesenchymal transition and promotes fibrosis: implications in neovascular age-related macular degeneration and treatment.

Authors:  Haibo Wang; Aniket Ramshekar; Eric Kunz; M Elizabeth Hartnett
Journal:  Angiogenesis       Date:  2021-02-28       Impact factor: 10.658

2.  Inhibition of epithelial-mesenchymal transition in retinal pigment epithelial cells by a retinoic acid receptor-α agonist.

Authors:  Yuka Kobayashi; Kazuhiro Tokuda; Chiemi Yamashiro; Fumiaki Higashijima; Takuya Yoshimoto; Manami Ota; Tadahiko Ogata; Atsushige Ashimori; Makoto Hatano; Masaaki Kobayashi; Sho-Hei Uchi; Makiko Wakuta; Kazuhiro Kimura
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

3.  Baseline predictors for subretinal fibrosis in neovascular age-related macular degeneration.

Authors:  Philipp K Roberts; Markus Schranz; Alice Motschi; Sylvia Desissaire; Valentin Hacker; Michael Pircher; Stefan Sacu; Wolf Buehl; Christoph K Hitzenberger; Ursula M Schmidt-Erfurth
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

4.  Morphologic and Microvascular Differences Between Macular Neovascularization With and Without Subretinal Fibrosis.

Authors:  Philipp Ken Roberts; Markus Schranz; Alice Motschi; Sylvia Desissaire; Valentin Hacker; Michael Pircher; Stefan Sacu; Wolf Buehl; Christoph Konrad Hitzenberger; Ursula Schmidt-Erfurth
Journal:  Transl Vis Sci Technol       Date:  2021-12-01       Impact factor: 3.283

5.  Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV.

Authors:  Chinmayi Himanshuroy Vyas; Chui Ming Gemmy Cheung; Janice Marie N Jordan-Yu; Hitoshi Shimizu; Anna Cheng Sim Tan; Shaun Sebastian Sim; Beau James Fenner; Masahiro Akiba; Usha Chakravarthy; Kelvin Yi Chong Teo
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

6.  Macrophage elastase (MMP12) critically contributes to the development of subretinal fibrosis.

Authors:  Caijiao Yi; Jian Liu; Wen Deng; Chang Luo; Jinyan Qi; Mei Chen; Heping Xu
Journal:  J Neuroinflammation       Date:  2022-04-05       Impact factor: 9.587

Review 7.  Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives.

Authors:  Louis Tenbrock; Julian Wolf; Stefaniya Boneva; Anja Schlecht; Hansjürgen Agostini; Peter Wieghofer; Günther Schlunck; Clemens Lange
Journal:  Cell Tissue Res       Date:  2021-09-03       Impact factor: 5.249

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.